# John M Lachin

List of Publications by Year
in descending order

| 255 papers | 64,943 citations | 3919 88 h-index | 750 250 g-index |
|---|---|---|---|
| 278 all docs | 278 docs citations | 278 times ranked | 43763 citing authors |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1 | Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. New England Journal of Medicine, 2002, 346, 393-403. | 13.9 | 16,031 |
| 2 | Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 2015, 373, 2117-2128. | 13.9 | 8,841 |
| 3 | Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. New England Journal of Medicine, 2005, 353, 2643-2653. | 13.9 | 4,433 |
| 4 | Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 323-334. | 13.9 | 2,809 |
| 5 | Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. New England Journal of Medicine, 2006, 355, 2427-2443. | 13.9 | 2,714 |
| 6 | Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2015, 373, 232-242. | 13.9 | 2,188 |
| 7 | Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive Therapy. New England Journal of Medicine, 2000, 342, 381-389. | 13.9 | 1,460 |
| 8 | Effect of Weight Loss With Lifestyle Intervention on Risk of Diabetes. Diabetes Care, 2006, 29, 2102-2107. | 4.3 | 1,050 |
| 9 | Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function. New England Journal of Medicine, 2009, 361, 2143-2152. | 13.9 | 900 |
| 10 | Introduction to sample size determination and power analysis for clinical trials. Contemporary Clinical Trials, 1981, 2, 93-113. | 2.0 | 897 |
| 11 | Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus. New England Journal of Medicine, 2002, 346, 1685-1691. | 13.9 | 793 |
| 12 | Intensive Diabetes Therapy and Carotid Intima–Media Thickness in Type 1 Diabetes Mellitus. New England Journal of Medicine, 2003, 348, 2294-2303. | 13.9 | 761 |
| 13 | Statistical Considerations in the Intent-to-Treat Principle. Contemporary Clinical Trials, 2000, 21, 167-189. | 2.0 | 543 |
| 14 | How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care, 2018, 41, 356-363. | 4.3 | 534 |
| 15 | Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes. New England Journal of Medicine, 2011, 365, 2366-2376. | 13.9 | 507 |
| 16 | Rosiglitazone-Associated Fractures in Type 2 Diabetes. Diabetes Care, 2008, 31, 845-851. | 4.3 | 498 |
| 17 | Differences in A1C by Race and Ethnicity Among Patients With Impaired Glucose Tolerance in the Diabetes Prevention Program. Diabetes Care, 2007, 30, 2453-2457. | 4.3 | 479 |
| 18 | Achieving Weight and Activity Goals Among Diabetes Prevention Program Lifestyle Participants. Obesity, 2004, 12, 1426-1434. | 4.0 | 470 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 19 | A Controlled Trial of Plasmapheresis Therapy in Severe Lupus Nephritis. New England Journal of Medicine, 1992, 326, 1373-1379. | 13.9 | 459 |
| 20 | Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited. Diabetes, 2008, 57, 995-1001. | 0.3 | 432 |
| 21 | Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality. JAMA - Journal of the American Medical Association, 2015, 313, 45. | 3.8 | 369 |
| 22 | Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation, 2018, 137, 119-129. | 1.6 | 347 |
| 23 | Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification. Biometrics, 1986, 42, 507. | 0.8 | 343 |
| 24 | Costs Associated With the Primary Prevention of Type 2 Diabetes Mellitus in the Diabetes Prevention Program. Diabetes Care, 2003, 26, 36-47. | 4.3 | 322 |
| 25 | Effect of Prior Intensive Insulin Treatment During the Diabetes Control and Complications Trial (DCCT) on Peripheral Neuropathy in Type 1 Diabetes During the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care, 2010, 33, 1090-1096. | 4.3 | 315 |
| 26 | A Controlled Clinical Trial of Dichloroacetate for Treatment of Lactic Acidosis in Adults. New England Journal of Medicine, 1992, 327, 1564-1569. | 13.9 | 312 |
| 27 | Prolonged Effect of Intensive Therapy on the Risk of Retinopathy Complications in Patients With Type 1 Diabetes Mellitus. JAMA Ophthalmology, 2008, 126, 1707. | 2.6 | 301 |
| 28 | Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and Microalbuminuria&lt;subtitle&gt;An Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort&lt;/subtitle&gt;&lt;alt-title&gt;Microalbuminuria Outcomes in Type 1 Diabetes&lt;/alt-title&gt;. Archives of Internal Medicine, 2011, 171, 412. | 4.3 | 298 |
| 29 | Properties of the urn randomization in clinical trials. Contemporary Clinical Trials, 1988, 9, 345-364. | 2.0 | 277 |
| 30 | Effects of Prior Intensive Insulin Therapy on Cardiac Autonomic Nervous System Function in Type 1 Diabetes Mellitus. Circulation, 2009, 119, 2886-2893. | 1.6 | 271 |
| 31 | Fall in C-Peptide During First 2 Years From Diagnosis. Diabetes, 2012, 61, 2066-2073. | 0.3 | 270 |
| 32 | Effect of Intensive Diabetes Therapy on the Progression of Diabetic Retinopathy in Patients With Type 1 Diabetes: 18 Years of Follow-up in the DCCT/EDIC. Diabetes, 2015, 64, 631-642. | 0.3 | 261 |
| 33 | Development and Progression of Renal Insufficiency With and Without Albuminuria in Adults With Type 1 Diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care, 2010, 33, 1536-1543. | 4.3 | 257 |
| 34 | Properties of permuted-block randomization in clinical trials. Contemporary Clinical Trials, 1988, 9, 327-344. | 2.0 | 256 |
| 35 | Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of Î²-Cell Function in Therapeutic Trials in Type 1 Diabetes. Diabetes Care, 2008, 31, 1966-1971. | 4.3 | 250 |
| 36 | The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes, 2006, 55, 3556-3565. | 0.3 | 238 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 37 | Randomization in clinical trials: Conclusions and recommendations. Contemporary Clinical Trials, 1988, 9, 365-374. | 2.0 | 236 |
| 38 | Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes and Endocrinology,the, 2019, 7, 128-139. | 5.5 | 223 |
| 39 | Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care, 2013, 36, 2254-2261. | 4.3 | 217 |
| 40 | A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care, 2002, 25, 1737-1743. | 4.3 | 215 |
| 41 | Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Advances and Contributions. Diabetes, 2013, 62, 3976-3986. | 0.3 | 215 |
| 42 | Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT. Diabetes, 2011, 60, 1552-1560. | 0.3 | 208 |
| 43 | Evaluating the Role of Epigenetic Histone Modifications in the Metabolic Memory of Type 1 Diabetes. Diabetes, 2014, 63, 1748-1762. | 0.3 | 208 |
| 44 | Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 2016, 374, 1092-1094. | 13.9 | 208 |
| 45 | Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial. Diabetes, 2014, 63, 739-748. | 0.3 | 201 |
| 46 | The role of measurement reliability in clinical trials. Clinical Trials, 2004, 1, 553-566. | 0.7 | 199 |
| 47 | Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. European Heart Journal, 2018, 39, 363-370. | 1.0 | 199 |
| 48 | Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovascular Diabetology, 2014, 13, 102. | 2.7 | 198 |
| 49 | Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA<sup>®</sup>). Diabetes and Vascular Disease Research, 2015, 12, 164-174. | 0.9 | 197 |
| 50 | Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. JAMA Cardiology, 2016, 1, 126. | 3.0 | 196 |
| 51 | Natural history and course of acquired lactic acidosis in adults. American Journal of Medicine, 1994, 97, 47-54. | 0.6 | 194 |
| 52 | Statistical properties of randomization in clinical trials. Contemporary Clinical Trials, 1988, 9, 289-311. | 2.0 | 186 |
| 53 | A review of methods for futility stopping based on conditional power. Statistics in Medicine, 2005, 24, 2747-2764. | 0.8 | 186 |
| 54 | Relationship of Glycated Albumin to Blood Glucose and HbA1c Values and to Retinopathy, Nephropathy, and Cardiovascular Outcomes in the DCCT/EDIC Study. Diabetes, 2014, 63, 282-290. | 0.3 | 186 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 55 | Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3002-11. | 3.3 | 179 |
| 56 | Fallacies of last observation carried forward analyses. Clinical Trials, 2016, 13, 161-168. | 0.7 | 174 |
| 57 | Update on Cardiovascular Outcomes at 30 Years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care, 2014, 37, 39-43. | 4.3 | 173 |
| 58 | Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes. Diabetes, 2006, 55, 2357-2364. | 0.3 | 169 |
| 59 | Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 134-142. | 1.8 | 164 |
| 60 | The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatric Diabetes, 2009, 10, 97-104. | 1.2 | 160 |
| 61 | Properties of simple randomization in clinical trials. Contemporary Clinical Trials, 1988, 9, 312-326. | 2.0 | 144 |
| 62 | Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care, 2017, 40, 777-783. | 4.3 | 141 |
| 63 | Worst-Rank Score Analysis with Informatively Missing Observations in Clinical Trials. Contemporary Clinical Trials, 1999, 20, 408-422. | 2.0 | 140 |
| 64 | Failure to Preserve Î²-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New- Onset Type 1 Diabetes. Diabetes Care, 2010, 33, 826-832. | 4.3 | 140 |
| 65 | Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial. Diabetes and Vascular Disease Research, 2013, 10, 289-301. | 0.9 | 132 |
| 66 | Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. American Journal of Clinical Nutrition, 2009, 89, 518-524. | 2.2 | 128 |
| 67 | Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp. Diabetes Care, 2018, 41, 1696-1706. | 4.3 | 127 |
| 68 | Analysis of Recurrent Events: Nonparametric Methods for Random-Interval Count Data. Journal of the American Statistical Association, 1988, 83, 339-347. | 1.8 | 119 |
| 69 | Skin Advanced Glycation End Products Glucosepane and Methylglyoxal Hydroimidazolone Are Independently Associated With Long-term Microvascular Complication Progression of Type 1 Diabetes. Diabetes, 2015, 64, 266-278. | 0.3 | 115 |
| 70 | Low-Dose Anti-Thymocyte Globulin (ATG) Preserves Î²-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care, 2018, 41, 1917-1925. | 4.3 | 114 |
| 71 | Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care, 2019, 42, 875-882. | 4.3 | 114 |
| 72 | Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. Stroke, 2017, 48, 1218-1225. | 1.0 | 112 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 73 | Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care, 2018, 41, 1717-1725. | 4.3 | 112 |
| 74 | Progression of Carotid Artery Intima-Media Thickness During 12 Years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes, 2011, 60, 607-613. | 0.3 | 109 |
| 75 | DCCT and EDIC Studies in Type 1 Diabetes: Lessons for Diabetic Neuropathy Regarding Metabolic Memory and Natural History. Current Diabetes Reports, 2010, 10, 276-282. | 1.7 | 108 |
| 76 | Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care, 2017, 40, 1010-1016. | 4.3 | 108 |
| 77 | Pretreatment Biliary Lipid Composition in White Patients with Radiol0ucent Gallstones in the National Cooperative Gallstone Study. Gastroenterology, 1982, 83, 738-752. | 0.6 | 107 |
| 78 | Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes, 2020, 69, 1000-1010. | 0.3 | 106 |
| 79 | Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations. Statistics in Medicine, 1992, 11, 1151-1170. | 0.8 | 105 |
| 80 | A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. Diabetes Care, 2018, 41, 1887-1894. | 4.3 | 104 |
| 81 | A Genome-Wide Association Study Identifies a Novel Major Locus for Glycemic Control in Type 1 Diabetes, as Measured by Both A1C and Glucose. Diabetes, 2010, 59, 539-549. | 0.3 | 103 |
| 82 | Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. New England Journal of Medicine, 2017, 376, 1507-1516. | 13.9 | 101 |
| 83 | A Risk Score for Type 1 Diabetes Derived From Autoantibody-Positive Participants in the Diabetes Prevention Trial–Type 1. Diabetes Care, 2008, 31, 528-533. | 4.3 | 98 |
| 84 | Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus. Archives of Internal Medicine, 2008, 168, 1867. | 4.3 | 98 |
| 85 | Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1969-1977. | 2.2 | 93 |
| 86 | The use of response-adaptive designs in clinical trials. Contemporary Clinical Trials, 1993, 14, 471-484. | 2.0 | 92 |
| 87 | Type 1 Diabetes TrialNet–An International Collaborative Clinical Trials Network. Annals of the New York Academy of Sciences, 2008, 1150, 14-24. | 1.8 | 92 |
| 88 | Validity and Reproducibility of Measurement of Islet Autoreactivity by T-Cell Assays in Subjects With Early Type 1 Diabetes. Diabetes, 2009, 58, 2588-2595. | 0.3 | 92 |
| 89 | Effect of rituximab on human in vivo antibody immune responses. Journal of Allergy and Clinical Immunology, 2011, 128, 1295-1302.e5. | 1.5 | 91 |
| 90 | Multiple Superoxide Dismutase 1/Splicing Factor Serine Alanine 15 Variants Are Associated With the Development and Progression of Diabetic Nephropathy. Diabetes, 2008, 57, 218-228. | 0.3 | 89 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 91 | Intensive Diabetes Therapy and Ocular Surgery in Type 1 Diabetes. New England Journal of Medicine, 2015, 372, 1722-1733. | 13.9 | 86 |
| 92 | Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program. Diabetes, 2007, 56, 1153-1159. | 0.3 | 84 |
| 93 | National Cooperative Gallstone Study. Gastroenterology, 1982, 82, 638-646. | 0.6 | 82 |
| 94 | Levels of Oxidized LDL and Advanced Glycation End Products–Modified LDL in Circulating Immune Complexes Are Strongly Associated With Increased Levels of Carotid Intima-Media Thickness and Its Progression in Type 1 Diabetes. Diabetes, 2011, 60, 582-589. | 0.3 | 82 |
| 95 | Effect of Intensive Glycemic Therapy on Erectile Function in Men With Type 1 Diabetes. Journal of Urology, 2011, 185, 1828-1834. | 0.2 | 80 |
| 96 | Myocardial Structure, Function, and Scar in Patients With Type 1 Diabetes Mellitus. Circulation, 2011, 124, 1737-1746. | 1.6 | 80 |
| 97 | Large sample inference for a win ratio analysis of a composite outcome based on prioritized components. Biostatistics, 2016, 17, 178-187. | 0.9 | 77 |
| 98 | Renal Outcomes in Patients with Type 1 Diabetes and Macroalbuminuria. Journal of the American Society of Nephrology: JASN, 2014, 25, 2342-2350. | 3.0 | 76 |
| 99 | Risk Factors for Kidney Disease in Type 1 Diabetes. Diabetes Care, 2019, 42, 883-890. | 4.3 | 76 |
| 100 | Parametric survival models for interval-censored data with time-dependent covariates. Biostatistics, 2006, 7, 599-614. | 0.9 | 72 |
| 101 | Implementation of Group Sequential Logrank Tests in a Maximum Duration Trial. Biometrics, 1990, 46, 759. | 0.8 | 69 |
| 102 | The Effect of Intensive Diabetes Treatment on Resting Heart Rate in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care, 2007, 30, 2107-2112. | 4.3 | 68 |
| 103 | Increased T Cell Proliferative Responses to Islet Antigens Identify Clinical Responders to Anti-CD20 Monoclonal Antibody (Rituximab) Therapy in Type 1 Diabetes. Journal of Immunology, 2011, 187, 1998-2005. | 0.4 | 65 |
| 104 | Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1032-1040. | 2.2 | 64 |
| 105 | The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study. Diabetologia, 2017, 60, 2084-2091. | 2.9 | 62 |
| 106 | Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care, 2020, 43, 867-874. | 4.3 | 61 |
| 107 | Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. Diabetes Care, 2017, 40, 1763-1770. | 4.3 | 60 |
| 108 | Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. Diabetes Care, 2018, 41, 596-603. | 4.3 | 59 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 109 | Sample Size Determinations for r x c Comparative Trials. Biometrics, 1977, 33, 315. | 0.8 | 58 |
| 110 | Power and sample size evaluation for the mcnemar test with application to matched case-control studies. Statistics in Medicine, 1992, 11, 1239-1251. | 0.8 | 57 |
| 111 | The Hemoglobin Glycation Index Is Not an Independent Predictor of the Risk of Microvascular Complications in the Diabetes Control and Complications Trial. Diabetes, 2007, 56, 1913-1921. | 0.3 | 57 |
| 112 | Lack of Durable Improvements in Î²-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care, 2019, 42, 1742-1751. | 4.3 | 56 |
| 113 | Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study. Lancet Diabetes and Endocrinology,the, 2021, 9, 436-445. | 5.5 | 56 |
| 114 | Circulating Vitamin D Metabolites and Kidney Disease in Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4780-4788. | 1.8 | 55 |
| 115 | Depression as a symptom of alcoholism: Search for a phenomenon.. Journal of Abnormal Psychology, 1968, 73, 195-197. | 2.0 | 55 |
| 116 | DNA methylation mediates development of HbA1c-associated complications in type 1 diabetes. Nature Metabolism, 2020, 2, 744-762. | 5.1 | 53 |
| 117 | Interim analyses with repeated measurements in a sequential clinical trial. Biometrika, 1990, 77, 359-364. | 1.3 | 51 |
| 118 | A Prospective Morphologic Evaluation of Hepatic Toxicity of Chenodeoxycholic Acid in Patients with Cholelithiasis: The National Cooperative Gallstone Study. Hepatology, 1982, 2, 187S-201S. | 3.6 | 51 |
| 119 | Sample size evaluation for a multiply matched case–control study using the score test from a conditional logistic (discrete Cox PH) regression model. Statistics in Medicine, 2008, 27, 2509-2523. | 0.8 | 50 |
| 120 | Determining Stability of Stored Samples Retrospectively: The Validation of Glycated Albumin. Clinical Chemistry, 2011, 57, 286-290. | 1.5 | 50 |
| 121 | Pancreatic Safety of Sitagliptin in the TECOS Study. Diabetes Care, 2017, 40, 164-170. | 4.3 | 49 |
| 122 | The Association of Coronary Artery Calcification With Subsequent Incidence of Cardiovascular Disease in Type 1 Diabetes. JACC: Cardiovascular Imaging, 2019, 12, 1341-1349. | 2.3 | 47 |
| 123 | Comparison of Urinary Albumin-Creatinine Ratio and Albumin Excretion Rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1235-1242. | 2.2 | 46 |
| 124 | The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. Journal of Diabetes and Its Complications, 2013, 27, 141-149. | 1.2 | 46 |
| 125 | Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes. Cardiovascular Diabetology, 2015, 14, 118. | 2.7 | 46 |
| 126 | Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA€REG OUTCOME trial. ESC Heart Failure, 2021, 8, 4517-4527. | 1.4 | 46 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 127 | Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis, 2011, 214, 462-467. | 0.4 | 43 |
| 128 | Factors Affecting the Decline in Incidence of Diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes, 2015, 64, 989-998. | 0.3 | 43 |
| 129 | Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care, 2019, 42, 1284-1289. | 4.3 | 42 |
| 130 | Residual Î² cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia. Journal of Clinical Investigation, 2021, 131, . | 3.9 | 42 |
| 131 | Group Sequential Distribution-Free Methods for the Analysis of Multivariate Observations. Biometrics, 1992, 48, 1033. | 0.8 | 41 |
| 132 | Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain: Observations from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care, 2010, 33, 177-183. | 4.3 | 40 |
| 133 | Longitudinal Changes in Estimated and Measured GFR in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2014, 25, 810-818. | 3.0 | 40 |
| 134 | Link-Based Models for Survival Data with Interval and Continuous Time Censoring. Biometrics, 1997, 53, 1199. | 0.8 | 39 |
| 135 | Effects of Prior Intensive Versus Conventional Therapy and History of Glycemia on Cardiac Function in Type 1 Diabetes in the DCCT/EDIC. Diabetes, 2013, 62, 3561-3569. | 0.3 | 38 |
| 136 | Association of Cardiovascular Risk Factors and Myocardial Fibrosis With Early Cardiac Dysfunction in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care, 2017, 40, 405-411. | 4.3 | 38 |
| 137 | Assessment of stratum-covariate interactions in Cox's proportional hazards regression model. Statistics in Medicine, 1986, 5, 73-83. | 0.8 | 37 |
| 138 | High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation, 2012, 27, 1416-1423. | 0.4 | 37 |
| 139 | Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 854-861. | 2.2 | 37 |
| 140 | Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC). Diabetes Care, 2021, 44, 2216-2224. | 4.3 | 37 |
| 141 | Sample Size Requirements for Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Type 1 Diabetes. PLoS ONE, 2011, 6, e26471. | 1.1 | 37 |
| 142 | Haptoglobin Genotype and the Rate of Renal Function Decline in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes, 2013, 62, 3218-3223. | 0.3 | 36 |
| 143 | Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease. Journal of the American College of Cardiology, 2018, 71, 364-367. | 1.2 | 35 |
| 144 | Ultrastructural Evidence of Intrahepatic Cholestasis Before and After Chenodeoxycholic Acid Therapy in Patients with Cholelithiasis: The National Cooperative Gallstone Study. Hepatology, 2007, 3, 209-220. | 3.6 | 32 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 145 | Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care, 2019, 42, 657-664. | 4.3 | 32 |
| 146 | On Stepwise Discriminant Analyses Applied to Physiologic Data. Psychophysiology, 1974, 11, 703-709. | 1.2 | 31 |
| 147 | Circulating Vitamin D Metabolites and Subclinical Atherosclerosis in Type 1 Diabetes. Diabetes Care, 2013, 36, 2423-2429. | 4.3 | 30 |
| 148 | Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. Circulation, 2018, 138, 1599-1601. | 1.6 | 28 |
| 149 | Analysis of Recurrent Events: Nonparametric Methods for Random-Interval Count Data. , 0, . |  | 28 |
| 150 | Applications of the Wei-Lachin Multivariate One-Sided Test for Multiple Outcomes on Possibly Different Scales. PLoS ONE, 2014, 9, e108784. | 1.1 | 27 |
| 151 | Hearing Impairment and Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. Diabetes Care, 2018, 41, 2495-2501. | 4.3 | 27 |
| 152 | Termination of a clinical trial with no treatment group difference: The Lupus Nephritis Collaborative Study. Contemporary Clinical Trials, 1992, 13, 62-79. | 2.0 | 26 |
| 153 | Gaps in the Glycation Gap Hypothesis. Clinical Chemistry, 2011, 57, 150-152. | 1.5 | 26 |
| 154 | The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes. Journal of Diabetes and Its Complications, 2015, 29, 108-114. | 1.2 | 26 |
| 155 | What are the clinical, quality-of-life, and cost consequences of 30â€ years of excellent vs. poor glycemic control in type 1 diabetes?. Journal of Diabetes and Its Complications, 2018, 32, 911-915. | 1.2 | 26 |
| 156 | Use of spending functions for occasional or continuous monitoring of data in clinical trials. Statistics in Medicine, 1993, 12, 2219-2231. | 0.8 | 25 |
| 157 | Application of the Weiâ€"Lachin multivariate one-directional test to multiple event-time outcomes. Clinical Trials, 2015, 12, 627-633. | 0.7 | 25 |
| 158 | Power and sample size evaluation for the Cochranâ€"Mantelâ€"Haenszel mean score (Wilcoxon rank) Tj ETQq0 0 0 rgBT /Overlock 10 Tf | 0.8 | 24 |
| 159 | Aortic Distensibility in Type 1 Diabetes. Diabetes Care, 2013, 36, 2380-2387. | 4.3 | 23 |
| 160 | Estimators and Tests in the Analysis of Multiple Nonindependent 2 X 2 Tables with Partially Missing Observations. Biometrics, 1988, 44, 513. | 0.8 | 22 |
| 161 | Sequential Monitoring of Survival Data with the Wilcoxon Statistic. Biometrics, 1995, 51, 1175. | 0.8 | 21 |
| 162 | Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit. Clinical Trials, 2009, 6, 565-573. | 0.7 | 21 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 163 | Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in typeâ€‰1 diabetes patients. Journal of Diabetes Investigation, 2022, 13, 125-133. | 1.1 | 21 |
| 164 | The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes. Diabetes Care, 2021, 44, 2225-2230. | 4.3 | 21 |
| 165 | Haptoglobin 2â€"2 genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Journal of Diabetes and Its Complications, 2016, 30, 1577-1584. | 1.2 | 20 |
| 166 | OGTT Glucose Response Curves, Insulin Sensitivity, and Î²-Cell Function in RISE: Comparison Between Youth and Adults at Randomization and in Response to Interventions to Preserve Î²-Cell Function. Diabetes Care, 2021, 44, 817-825. | 4.3 | 20 |
| 167 | Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes. Diabetes Care, 2021, 44, 1499-1505. | 4.3 | 20 |
| 168 | Skin collagen fluorophore LW-1 versus skin fluorescence as markers for the long-term progression of subclinical macrovascular disease in type 1 diabetes. Cardiovascular Diabetology, 2016, 15, 30. | 2.7 | 19 |
| 169 | An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC Study. Diabetes Care, 2020, 43, 2478-2484. | 4.3 | 19 |
| 170 | Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study. Lancet Diabetes and Endocrinology,the, 2022, 10, 509-518. | 5.5 | 19 |
| 171 | Pilot Genome-Wide Association Search Identifies Potential Loci for Risk of Erectile Dysfunction in Type 1 Diabetes Using the DCCT/EDIC Study Cohort. Journal of Urology, 2012, 188, 514-520. | 0.2 | 18 |
| 172 | Progression of Electrocardiographic Abnormalities in Type 1 Diabetes During 16 Years of Followâ€up: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Journal of the American Heart Association, 2016, 5, e002882. | 1.6 | 18 |
| 173 | Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care, 2017, 40, 793-799. | 4.3 | 18 |
| 174 | Point: Intensive Glycemic Control and Mortality in ACCORDâ€"A Chance Finding?. Diabetes Care, 2010, 33, 2719-2721. | 4.3 | 17 |
| 175 | Association of Baseline Characteristics With Insulin Sensitivity and Î²-Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. Diabetes Care, 2021, 44, 340-349. | 4.3 | 16 |
| 176 | Immune Complexes and the Risk of CVD in Type 1 Diabetes. Diabetes, 2019, 68, 1853-1860. | 0.3 | 15 |
| 177 | Significance of Epicardial and Intrathoracic Adipose Tissue Volume among Type 1 Diabetes Patients in the DCCT/EDIC: A Pilot Study. PLoS ONE, 2016, 11, e0159958. | 1.1 | 15 |
| 178 | External monitoring of a data coordinating center: Experience of the national cooperative gallstone study. Contemporary Clinical Trials, 1987, 8, 1-11. | 2.0 | 14 |
| 179 | GROUP SEQUENTIAL MONITORING OF DISTRIBUTION-FREE ANALYSES OF REPEATED MEASURES. Statistics in Medicine, 1997, 16, 653-668. | 0.8 | 14 |
| 180 | Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study. Diabetes Care, 2022, 45, 659-665. | 4.3 | 14 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 181 | Properties of randomization in clinical trials: Foreword. Contemporary Clinical Trials, 1988, 9, 287-288. | 2.0 | 13 |
| 182 | Over-ruling a group sequential boundary?a stopping rule versus a guideline. Statistics in Medicine, 2003, 22, 3347-3355. | 0.8 | 13 |
| 183 | Sample size and power for a logrank test and Cox proportional hazards model with multiple groups and strata, or a quantitative covariate with multiple strata. Statistics in Medicine, 2013, 32, 4413-4425. | 0.8 | 13 |
| 184 | Mediation of the association of smoking and microvascular complications by glycemic control in type 1 diabetes. PLoS ONE, 2019, 14, e0210367. | 1.1 | 13 |
| 185 | Sequential Clinical Trials for Normal Variates Using Interval Composite Hypotheses. Biometrics, 1981, 37, 87. | 0.8 | 12 |
| 186 | Operating characteristics of sample size re-estimation with futility stopping based on conditional power. Statistics in Medicine, 2006, 25, 3348-3365. | 0.8 | 12 |
| 187 | A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. Pediatric Diabetes, 2011, 12, 85-90. | 1.2 | 12 |
| 188 | Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events. Hypertension, 2017, 70, 907-914. | 1.3 | 12 |
| 189 | Shape of the OGTT glucose response curve: relationship with Î²-cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin. BMJ Open Diabetes Research and Care, 2021, 9, e002264. | 1.2 | 12 |
| 190 | Plasma advanced glycation end products and the subsequent risk of microvascular complications in type 1 diabetes in the DCCT/EDIC. BMJ Open Diabetes Research and Care, 2022, 10, e002667. | 1.2 | 12 |
| 191 | Central laboratory quality control in the national cooperative gallstone study. Contemporary Clinical Trials, 1983, 4, 101-123. | 2.0 | 11 |
| 192 | A Flexible Stochastic Curtailing Procedure for the Log-Rank Test. Contemporary Clinical Trials, 2000, 21, 428-439. | 2.0 | 11 |
| 193 | Application of robust estimating equations to the analysis of quantitative longitudinal data. Statistics in Medicine, 2001, 20, 3411-3428. | 0.8 | 11 |
| 194 | Biological Variation in HbA1c Predicts Risk of Retinopathy and Nephropathy in Type 1 Diabetes: Response to McCarter et al.. Diabetes Care, 2005, 28, 233-233. | 4.3 | 11 |
| 195 | Nonparametric Statistical Analysis. JAMA - Journal of the American Medical Association, 2020, 323, 2080. | 3.8 | 11 |
| 196 | Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies. PLoS ONE, 2021, 16, e0257154. | 1.1 | 11 |
| 197 | Conflicts of interest in data monitoring of industry versus publicly financed clinical trials. Statistics in Medicine, 2004, 23, 1519-1521. | 0.8 | 10 |
| 198 | On a Stepwise Procedure for Two Population Bayes Decision Rules Using Discrete Variables. Biometrics, 1973, 29, 551. | 0.8 | 9 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 199 | The National Cooperative Gallstone Study and current management of cholesterol cholelithiasis—Two views. Gastroenterology, 1983, 84, 644-648. | 0.6 | 9 |
| 200 | Validity of Self-Report in Type 1 Diabetic Subjects for Laser Treatment of Retinopathy. Ophthalmology, 2013, 120, 2580-2586. | 2.5 | 9 |
| 201 | Biomarkers of tubulointerstitial damage and function in type 1 diabetes. BMJ Open Diabetes Research and Care, 2017, 5, e000461. | 1.2 | 9 |
| 202 | Association of Habitual Daily Physical Activity With Glucose Tolerance and β-Cell Function in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study. Diabetes Care, 2019, 42, 1521-1529. | 4.3 | 9 |
| 203 | Moderation of the effect of glycemia on the risk of cardiovascular disease in type 1 diabetes: The DCCT/EDIC study. Diabetes Research and Clinical Practice, 2021, 171, 108591. | 1.1 | 9 |
| 204 | Hyperglucagonemia Does Not Explain the β-Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study. Diabetes Care, 2021, 44, 1961-1969. | 4.3 | 9 |
| 205 | Optimal screening schedules for disease progression with application to diabetic retinopathy. Biostatistics, 2018, 19, 1-13. | 0.9 | 9 |
| 206 | Biochemical Markers of Bone Turnover in Older Adults With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2405-e2416. | 1.8 | 9 |
| 207 | Distribution-Free Marginal Analysis of Repeated Measures. Drug Information Journal, 1996, 30, 1017-1028. | 0.5 | 8 |
| 208 | Relation Between Carotid Intima–Media Thickness and Left Ventricular Mass in Type 1 Diabetes Mellitus (from the Epidemiology of Diabetes Interventions and Complications [EDIC] Study). American Journal of Cardiology, 2012, 110, 1534-1540. | 0.7 | 8 |
| 209 | Stratified-adjusted versus unstratified assessment of sample size and power for analyses of proportions. Cancer Treatment and Research, 1995, 75, 203-223. | 0.2 | 8 |
| 210 | Coronary Artery Disease Events and Carotid Intima–Media Thickness in Type 1 Diabetes in the DCCT/EDIC Cohort. Journal of the American Heart Association, 2021, 10, e022922. | 1.6 | 8 |
| 211 | The Society for Clinical Trials supports United States legislation mandating trials registration. Clinical Trials, 2004, 1, 417-420. | 0.7 | 7 |
| 212 | Maximum information designs. Clinical Trials, 2005, 2, 453-464. | 0.7 | 7 |
| 213 | Power of the Mantel–Haenszel and other tests for discrete or grouped time–to–event data under a chained binomial model. Statistics in Medicine, 2013, 32, 220-229. | 0.8 | 7 |
| 214 | Withdrawal of medications leads to worsening of <scp>OGTT</scp> parameters in youth with impaired glucose tolerance or <scp>recently‐diagnosed</scp> type 2 diabetes. Pediatric Diabetes, 2020, 21, 1437-1446. | 1.2 | 7 |
| 215 | Brain Structure Among Middle-aged and Older Adults With Long-standing Type 1 Diabetes in the DCCT/EDIC Study. Diabetes Care, 2022, 45, 1779-1787. | 4.3 | 7 |
| 216 | Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus: Insights From the DCCT/EDIC Study. Journal of the American Heart Association, 2018, 7, . | 1.6 | 5 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 217 | Risk Factors for Hearing Impairment in Type 1 Diabetes. Endocrine Practice, 2019, 25, 1243-1254. | 1.1 | 5 |
| 218 | Association of glycemia with insulin sensitivity and Î²-cell function in adults with early type 2 diabetes on metformin alone. Journal of Diabetes and Its Complications, 2021, 35, 107912. | 1.2 | 5 |
| 219 | Phasic Heart Rate Responses: Different Patterns in Black and in White Newborns. Psychosomatic Medicine, 1975, 37, 326-332. | 1.3 | 4 |
| 220 | Martingales without tears. Lifetime Data Analysis, 1995, 1, 361-375. | 0.4 | 4 |
| 221 | Refractive Error and Retinopathy Outcomes in Type 1 Diabetes. Ophthalmology, 2021, 128, 554-560. | 2.5 | 4 |
| 222 | Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care, 2021, 44, 1309-1316. | 4.3 | 4 |
| 223 | Effects of dose relative to body weight in the national cooperative gallstone study: A fixed-dose trial. Contemporary Clinical Trials, 1983, 4, 125-131. | 2.0 | 3 |
| 224 | Major issues in the organization and implementation of the national cooperative Gallstone Study (NCGS). Contemporary Clinical Trials, 1984, 5, 1-12. | 2.0 | 3 |
| 225 | Nonparametric test of stochastic ordering for multiple longitudinal measures. Journal of Biopharmaceutical Statistics, 1995, 5, 235-243. | 0.4 | 3 |
| 226 | Corrections for Bias in Maximum Likelihood Parameter Estimates Due to Nuisance Parameters. Communications in Statistics Part B: Simulation and Computation, 2003, 32, 619-639. | 0.6 | 3 |
| 227 | A composite design for transition from a preliminary to a full-scale study. Statistics in Medicine, 2007, 26, 5014-5032. | 0.8 | 3 |
| 228 | Comment on Novodvorsky et al. Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 Diabetes. Diabetes Care 2017;40:655â€"662. Diabetes Care, 2018, 41, e64-e64. | 4.3 | 3 |
| 229 | Properties of composite time to first event versus joint marginal analyses of multiple outcomes. Statistics in Medicine, 2018, 37, 3918-3930. | 0.8 | 3 |
| 230 | Worst-Rank Score Methodsâ€"A Nonparametric Approach to Informatively Missing Data. JAMA - Journal of the American Medical Association, 2020, 324, 1670. | 3.8 | 3 |
| 231 | Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. Diabetes 2020;69:291â€"299. Diabetes, 2020, 69, e7-e8. | 0.3 | 3 |
| 232 | Remembrances of Max Halperin. Statistics in Medicine, 1990, 9, 863-870. | 0.8 | 2 |
| 233 | Probabilistic measures of costâ€effectiveness. Statistics in Medicine, 2016, 35, 3976-3986. | 0.8 | 2 |
| 234 | Refining Measurement of Hemoglobin A1c. Clinical Chemistry, 2017, 63, 1433-1435. | 1.5 | 2 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 235 | Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care 2017;40:777â€"783. Diabetes Care, 2017, 40, e165-e166. | 4.3 | 2 |
| 236 | Longitudinal Plasma Kallikrein Levels and Their Association With the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC. Diabetes, 2020, 69, 2440-2445. | 0.3 | 2 |
| 237 | Models to Assess the Association of a Semiquantitative Exposure With Outcomes. American Journal of Epidemiology, 2020, 189, 1573-1582. | 1.6 | 2 |
| 238 | Severe hypoglycaemia in Diabetes Control and Complications Trial. Lancet, The, 1994, 343, 1097-1098. | 6.3 | 1 |
| 239 | Group sequential large sampleT2-like?2 tests for multivariate observations. Statistics in Medicine, 2003, 22, 3357-3368. | 0.8 | 1 |
| 240 | Methods for a longitudinal quantitative outcome with a multivariate Gaussian distribution multi-dimensionally censored by therapeutic intervention. Statistics in Medicine, 2014, 33, 1288-1306. | 0.8 | 1 |
| 241 | Data sharing is desirable, but benefits should not be exaggerated. BMJ, The, 2015, 351, h5508. | 3.0 | 1 |
| 242 | Closed testing using surrogate hypotheses with restricted alternatives. PLoS ONE, 2019, 14, e0219520. | 1.1 | 1 |
| 243 | Closed testing of each group versus the others combined in a multiple group analysis. Clinical Trials, 2020, 17, 77-86. | 0.7 | 1 |
| 244 | Identifying Change Points in a Covariate Effect on Time-to-Event Analysis with Reduced Isotonic Regression. PLoS ONE, 2014, 9, e113948. | 1.1 | 1 |
| 245 | Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. Diabetes Care, 2022, 45, 585-593. | 4.3 | 1 |
| 246 | Left Ventricular Structure, Tissue Composition, and Aortic Distensibility in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications. American Journal of Cardiology, 2022, 174, 158-165. | 0.7 | 1 |
| 247 | Permutation tests following restricted randomization procedures. Contemporary Clinical Trials, 1990, 11, 150-152. | 2.0 | 0 |
| 248 | Relationship of myocardial scar with cardiovascular disease risk factors in the diabetes control and complications trial (DCCT)/epidemiology of diabetes interventions and complications (EDIC) study. Journal of Cardiovascular Magnetic Resonance, 2010, 12, . | 1.6 | 0 |
| 249 | Reminiscences of Jerry Cornfield. Clinical Trials, 2013, 10, 337-339. | 0.7 | 0 |
| 250 | University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (afternoon panel session). Clinical Trials, 2018, 15, 366-385. | 0.7 | 0 |
| 251 | Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657â€"664. Diabetes Care, 2019, 42, e137-e137. | 4.3 | 0 |
| 252 | The minimum intensity of a mixed exposure that increases the risk of an outcome. Statistics in Medicine, 2020, 39, 4016-4024. | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 253 | Costâ€efficient clinical studies with continuous time survival outcomes. Statistics in Medicine, 2021, 40, 3682-3694. | 0.8 | 0 |
| 254 | Early Termination of the Diabetes Control and Complications Trial. , 2006, , 93-108. | | 0 |
| 255 | The Department of Statistics at The George Washington University. , 2012, , 65-76. | | 0 |